Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

544results about How to "Eliminate loss" patented technology

Delivery of therapeutic biologicals from implantable tissue matrices

InactiveUS6692738B2Many of effectMany of inconvenienceBiocidePowder deliveryProgenitorActive agent
Normal cells, such as fibroblasts or other tissue or organ cell types, are genetically engineered to express biologically active, therapeutic agents, such as proteins that are normally produced in small amounts, for example, MIS, or other members of the TGF-beta family Herceptin(TM), interferons, andanti-angiogenic factors. These cells are seeded into a matrix for implantation into the patient to be treated. Cells may also be engineered to include a lethal gene, so that implanted cells can be destroyed once treatment is completed. Cells can be implanted in a variety of different matrices. In a preferred embodiment, these matrices are implantable and biodegradable over a period of time equal to or less than the expected period of treatment, when cells engraft to form a functional tissue producing the desired biologically active agent. Implantation may be ectopic or in some cases orthotopic. Representative cell types include tissue specific cells, progenitor cells, and stem cells. Matrices can be formed of synthetic or natural materials, by chemical coupling at the time of implantation, using standard techniques for formation of fibrous matrices from polymeric fibers, and using micromachining or microfabrication techniques. These devices and strategies are used as delivery systems via standard or minimally invasive implantation techniques for any number of parenterally deliverable recombinant proteins, particularly those that are difficult to produce in large amounts and / or active forms using conventional methods of purification, for the treatment of a variety of conditions that produce abnormal growth, including treatment of malignant and benign neoplasias, vascular malformations (hemangiomas), inflammatory conditions, keloid formation, abdominal or plural adhesions, endometriosis, congenital or endocrine abnormalities, and other conditions that can produce abnormal growth such as infection. Efficacy of treatment with the therapeutic biologicals is detected by determining specific criteria, for example, cessation of cell proliferation, regression of abnormal tissue, or cell death, or expression of genes or proteins reflecting the above.
Owner:THE GENERAL HOSPITAL CORP

Microwave Transmission Line Integrated Microwave Generating Element and Microwave Transmission Line Integrated Microwave Detecting Element

Microwave generating and detection portions of a electronic circuit is improved in efficiency and reduced in size. A microwave generating element A comprises a lower electrode 1, a layer 3 formed on the lower electrode 1 in an island shape, forming a magnetoresistance element, an insulator 7 formed on the lower electrode 1 in such a manner as to surround the layer 3 forming the magnetoresistance element, and an upper electrode 5 formed on the insulator 7 and the layer 3 forming the magnetoresistance element. The layer 3 forming the magnetoresistance element includes, in order from the side of the lower electrode 1, a magnetization fixed layer 3a, an intermediate layer 3b, and a magnetization free layer 3c. The magnetization free layer 3c, which is required to produce resonance oscillation based on a current, preferably is dimensioned to be equal to or smaller than 200 nm square in a cross-sectional area and on the order of 1 to 5 nm in film thickness, for example. The magnetization fixed layer 3a, when made of a single material, is required to have a thickness 10 times or more of the thickness of the magnetization free layer 3c. The magnetization fixed layer 3a may be comprised of a magnetic metal multilayer film that utilizes antiferromagnetic coupling.
Owner:JAPAN SCI & TECH CORP

Delivery of therapeutic biologicals from implantable tissue matrices

InactiveUS20020031500A1Many of effectMany of inconveniencePowder deliveryBiocideProgenitorActive agent
Normal cells, such as fibroblasts or other tissue or organ cell types, are genetically engineered to express biologically active, therapeutic agents, such as proteins that are normally produced in small amounts, for example, MIS, or other members of the TGF-beta family Herceptin(TM), interferons, andanti-angiogenic factors. These cells are seeded into a matrix for implantation into the patient to be treated. Cells may also be engineered to include a lethal gene, so that implanted cells can be destroyed once treatment is completed. Cells can be implanted in a variety of different matrices. In a preferred embodiment, these matrices are implantable and biodegradable over a period of time equal to or less than the expected period of treatment, when cells engraft to form a functional tissue producing the desired biologically active agent. Implantation may be ectopic or in some cases orthotopic. Representative cell types include tissue specific cells, progenitor cells, and stem cells. Matrices can be formed of synthetic or natural materials, by chemical coupling at the time of implantation, using standard techniques for formation of fibrous matrices from polymeric fibers, and using micromachining or microfabrication techniques. These devices and strategies are used as delivery systems via standard or minimally invasive implantation techniques for any number of parenterally deliverable recombinant proteins, particularly those that are difficult to produce in large amounts and/or active forms using conventional methods of purification, for the treatment of a variety of conditions that produce abnormal growth, including treatment of malignant and benign neoplasias, vascular malformations (hemangiomas), inflammatory conditions, keloid formation, abdominal or plural adhesions, endometriosis, congenital or endocrine abnormalities, and other conditions that can produce abnormal growth such as infection. Efficacy of treatment with the therapeutic biologicals is detected by determining specific criteria, for example, cessation of cell proliferation, regression of abnormal tissue, or cell death, or expression of genes or proteins reflecting the above.
Owner:THE GENERAL HOSPITAL CORP

Smart home security system

The invention discloses a smart home security system. The smart home security system comprises a vibration sensor, a door and window magnetic sensor, an infrared sensor, a smoke sensor, a temperature sensor and a gas sensor, wherein the vibration sensor, the door and window magnetic sensor and the infrared sensor are connected with a signal processing circuit A respectively; the smoke sensor and the temperature sensor are connected with a signal processing circuit B respectively; the gas sensor is connected with a signal processing circuit C; the signal processing circuit A, the signal processing circuit B and the signal processing circuit C are connected with a power line carrier communication circuit respectively; the power line carrier communication circuit is connected with a microprocessor; the microprocessor is connected with a keyboard, a camera, a driving circuit, a display, a communication device, a voice alarm circuit and an Ethernet respectively; the driving circuit is connected with a relay; the relay is connected with an electric bell; the communication device is connected with a remote controller. The smart home security system can meet needs of people on theft prevention, fire prevention and gas poisoning prevention, is free of mistaken alarm and has an on-spot snapshot function.
Owner:CHENGDU XINXIN INFORMATION TECH

Passive noise shaping successive approximation SAR analog-to-digital converter

The invention discloses a passive noise shaping successive approximation SAR analog-to-digital converter. The analog-to-digital converter comprises three capacitive digital-to-analog converters (CDACs), a passive loop filter, a comparator and an SAR logic circuit, wherein the three identical CDACs comprise a CDAC1 required by normal SAR conversion and two auxiliary CDAC2 and CDAC3 used for generating a margin voltage of a previous period. Two interlaced CDAC2 and CDAC3 are added, and KT/C noise and gain loss introduced by passive margin sampling are removed. Wherein the CDAC1 generates the margin voltage Vres (n) of the current period, and the CDAC2 and the CDAC3 alternately generate the margin voltage Vres (n-1) of the previous period. And the passive loop filter carries out noise shapingon the margin voltage and suppresses in-band noise of the signal. And the comparator quantizes the analog output of the passive loop filter into a digital code, the digital code toggles the next capacitor switch in the CDAC through the SAR logic circuit until the conversion is finished, and all the digital codes are sequentially spliced together to serve as the output code of the SAR ADC, which is the same as that of the common SAR ADC. According to the invention, the second-order noise shaping effect can be realized, the signal in-band quantization noise and the comparator noise are effectively suppressed, and the signal-to-noise ratio and the spurious-free dynamic range of the SAR ADC are obviously improved.
Owner:SOUTHEAST UNIV

Loader constant and variable hydraulic system based on flow amplifying steering

ActiveCN104929183ALow powerProtect against high pressure shocksSoil-shifting machines/dredgersSolenoid valveEngineering
The invention discloses a loader constant and variable hydraulic system based on flow amplifying steering. The loader constant and variable hydraulic system comprises a hydraulic oil tank, a variable pump, a steering gear, a right limiting valve, a left limiting valve, a flow amplifying valve, a left steering cylinder, a right steering cylinder, a flow control valve block, an energy accumulator, a distribution valve, a tipping bucket cylinder, a movable arm cylinder, a pilot valve, an unloading valve block, a constant flow pump, a working mode switching electromagnetic valve and a working mode selector switch. The small-displacement steering gear is adopted to serve as a hydraulic pilot stage of the flow amplifying valve, throttling losses inside a coaxial flow amplifying steering gear in the rapid steering process can be removed, and fuel consumption is reduced; a low-cost home-made element is adopted to replace an inlet element, and steering stability of a variable system is achieved; a feedback signal of the flow amplifying valve is controlled in a time-shared manner, stability of a steering system is improved, and energy consumption is reduced; and meanwhile, the energy-saving effect and good control characteristics of the variable pump can be played out well, and the energy-saving effect and the control precision of a working system are improved.
Owner:XCMG CONSTR MACHINERY

Multicast method in wireless local area network

The invention discloses a method for executing multicast transmission in a media access control (MAC) layer of a wireless network, which comprises the steps as follows: a sender divides multicast group members into groups according to the channel conditions of the multicast group members and indicates a representative node of each group; the sender multicasts an MRTS (Marginal rate of technical substitution) containing the indication whether data packets to be sent to a multicast group exist to the multicast group members and waits for an MCTS from the representative node of each group; afterthe MCTS from the representative node of each group is received, the sender multicasts the data packets to the multicast group members and records the sequence number of the current sent data packet;and after receiving the multicast data packets, the representative node records a value that indicates whether the current sent data packet is correctly received in a bit mapping field of each MCTS and sends the MCTS to the sender after a preset time period. The sender judges whether data packet loss exists according to the recorded value in the bit mapping field of the MCTS from the representative node; and under the situation of data packet loss, the sender retransmits the lost data package when sending data packets next time.
Owner:NTT DOCOMO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products